Description de l'entreprise
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Conseil d'administration & Conseil de surveillance
| PDG |
| Jean-Christophe Tellier |
| Conseil d'administration |
| Sandrine Dufour, Charl van Zyl, Dhaval Patel, Emmanuel Caeymaex, Iris Löw-Friedrich, Jean Luc Fleurial, Kirsten Lund-Jurgensen, Denelle Waynick Johnson |
| Conseil de surveillance |
| Jonathan Peacock, Fiona du Monceau, Jean-Christophe Tellier, Jan Berger, Maëlys Castella, Kay Davies, Albrecht De Graeve, Susan Gasser, Pierre Gurdjian, Charles-Antoine Janssen, Cyril Janssen, Cédric van Rijckevorsel, Ulf Wiinberg, Viviane Monges |
Données de l'entreprise
| Nom: |
UCB SA |
| Adresse: |
Allée de la Recherche 60,B-1070 Brussels |
| Téléphone: |
+32-2-559-9999 |
| Fax: |
+32-2-559-9900 |
| Courriel: |
contactucb@ucb.com
|
| Internet: |
www.ucb.com/ |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
44.83% |
| IPO date: |
- |
